SCHEMBL24257576

SCHEMBL24257576

CCOC(=O)CNC(=O)c1ncc(-c2cnc(-c3ccccc3)s2)c(C)c1O

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 2/20 0.41
ALDH1A1 P00352 4/20 0.41
LMNA P02545 1/20 0.41
PPID Q08752 1/20 0.40
KMT2A Q03164 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MEN1 O00255 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
EGLN1 Q9GZT9 5/20 0.39
VEGFA P15692 1/20 0.39
FLT1 P17948 1/20 0.39
EGLN3 Q9H6Z9 1/20 0.39
KDM4E B2RXH2 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
HPGD P15428 1/20 0.38
CDC7 O00311 1/20 0.38
DBF4 Q9UBU7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257508 0.89 EGLN1 (0.49) EGLN1VEGFAFLT1EGLN3
SCHEMBL30546857 0.85 CDC7 (0.48) TRPM8ALDH1A1LMNAKMT2ASMN1; SMN2
SCHEMBL24257697 0.81 EGLN1 (0.50) EGLN1
Glycine SCHEMBL30546838 0.80 CDC7 (0.44) TRPM8ALDH1A1KMT2ASMN1; SMN2MEN1
SCHEMBL24257738 0.80 HDAC6 (0.43) ALDH1A1LMNAKMT2ASMN1; SMN2KDM4E
SCHEMBL30546822 0.80 ALDH1A1 (0.46) ALDH1A1LMNAPPIDKMT2ASMN1; SMN2
SCHEMBL30452553 0.80 ALDH1A1 (0.46) ALDH1A1LMNAPPIDKMT2ASMN1; SMN2
SCHEMBL24257545 0.80 ALDH1A1 (0.46) ALDH1A1LMNAPPIDKMT2ASMN1; SMN2
SCHEMBL24257683 0.78 LMNA (0.50) ALDH1A1LMNAPPIDSMN1; SMN2L3MBTL1
SCHEMBL30546867 0.78 LMNA (0.50) ALDH1A1LMNAPPIDSMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 TRPM8 4331/4885ALDH1A1 1362/4885LMNA 4120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.